-
The Companies manufacturing COVID-19 vaccination in India have given only "Emergency Use Authorization for vaccinating people of 18 years age and above
-
The Centre should consider utilising its position as the monopolistic buyer in the market and pass down the benefit to all people
-
US-based Ocugen will make an upfront payment and milestone payment upon first commercial sale in Canada to Bharat Biotech, in addition to sharing the profit from sales of Covaxin in Canada
-
The state had earlier announced that it would stop vaccination drive from Wednesday as it was running short of vaccines and that it would receive its quota of vaccines only on June 6.
-
Telangana govt must see that the gap between Covishield doses is reduced to enable students to plan their travel
-
India’s bitter standoff with Twitter, WhatsApp has cast a shadow over the trip, making Jaishankar’s task much more difficult
-
For vaccines to result in actual vaccination of people, highly coordinated efforts are required from international supply chains, manufacturers, regulators and State and Central government agencies, says Bharat Biotech
-
The process for getting approvals for the indigenous vaccine needs to be expedited to avoid hardships for millions of people
-
Anvisa recently approved the Covaxin clinical trial in Brazil, which will study the application of two doses, with 28 days of interval, involving 4,500 volunteers
-
Passengers arriving in Saudi Arabia must submit a vaccination certificate showing they have received the approved shot, according to guidelines issued by the General Authority of Civil Aviation
-
Anticipating the shortages, many States including Telangana had recently gone for global tenders
-
Regulatory approvals for Covaxin are in process in more than 60 countries including USA, Brazil and Hungary, says the Hyderabad company.
-
The daily vaccination rate has fallen to 1.3 million doses despite India not exporting the vaccines now
-
Hyderabad: Hyderabad-based Bharat Biotech said it will ramp up the manufacturing capacities for Covaxin, at Chiron Behring Vaccines, Ankleshwar Gujarat, a wholly owned subsidiary of Bharat Biotech. The company plans to produce 200 million (20 crore) doses of Covaxin per annum in the GMP facilities that are already operational for the production of vaccines based […]
-
Company plans to produce an additional 200 million doses of Covaxin per annum in the GMP facilities located at Ankleshwar, Gujarat, starting from the fourth quarter of 2021
-
People with comorbidities, belonging to this age group, are included in the first priority group, Health Department sources here said.
-
Hyderabad: The second dose of Covid vaccination for individuals above 45 years has been postponed in Telangana. Details regarding the resumption of vaccination drive will be made available subsequently, Director of Public Health, Dr G Srinivasa Rao said on Sunday. In a press note, Dr Rao said that in view of inadequate stock of Covaxin […]
-
He said that over 16 companies were assisting the Central government in producing vaccines
-
States/UTs have been requested to direct the officials concerned to ensure rational and judicious utilisation of allocated doses, said the Union Health Ministry
-
The Centre can use its powers under Section 92, 100 & 102 of the Patents Act to increase production of Covid vaccines